Dimitrov DS. Therapeutic proteins. Methods Mol Biol. 2012;899:1–26. https://doi.org/10.1007/978-1-61779-921-1_1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hoffman AS. The early days of PEG and PEGylation (1970s–1990s). Acta Biomater. 2016;40:1–5. https://doi.org/10.1016/j.actbio.2016.05.029.

Article  CAS  PubMed  Google Scholar 

López-Estevez AM, Gref R, Alonso MJ. A journey through the history of PEGylated drug delivery nanocarriers. Drug Deliv Transl Res. 2024;14:2026–31. https://doi.org/10.1007/s13346-024-01608-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao Y, Joshi M, Zhao Z, Mitragotri S. Pegylated therapeutics in the clinic. Bioeng Transl Med. 2024;9:e10600. https://doi.org/10.1002/btm2.10600.

Article  CAS  PubMed  Google Scholar 

Chen BM, Cheng TL, Roffler SR. Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies. ACS Nano. 2021;15:14022–48. https://doi.org/10.1021/acsnano.1c05922.

Article  CAS  PubMed  Google Scholar 

Bento C, Katz M, Santos MMM, Afonso CAM. Striving for uniformity: a review on advances and challenges to achieve uniform polyethylene glycol. Org Process Res Dev. 2024;28:860–90. https://doi.org/10.1021/acs.oprd.3c00428.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Turecek PL, Bossard MJ, Schoetens F, Ivens IA. Pegylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs. J Pharm Sci. 2016;105:460–75. https://doi.org/10.1016/j.xphs.2015.11.015.

Article  CAS  PubMed  Google Scholar 

Zhao T, Cheng YN, Tan HN, et al. Site-specific chemical modification of human serum albumin with polyethylene glycol prolongs half-life and improves intravascular retention in mice. Biol Pharm Bull. 2012;35:280–8. https://doi.org/10.1248/bpb.35.280.

Article  CAS  PubMed  Google Scholar 

Ibrahim M, Ramadan E, Elsadek NE, et al. Polyethylene glycol (PEG): the nature, immunogenicity, and role in the hypersensitivity of PEGylated products. J Control Release. 2022;351:215–30. https://doi.org/10.1016/j.jconrel.2022.09.031.

Article  CAS  PubMed  Google Scholar 

Baumann A, Tuerck D, Prabhu S, Dickmann L, Sims J. Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis? Drug Discov Today. 2014;19:1623–31. https://doi.org/10.1016/j.drudis.2014.06.002.

Article  CAS  PubMed  Google Scholar 

Ivens IA, Achanzar W, Baumann A, et al. PEGylated biopharmaceuticals: current experience and considerations for nonclinical development. Toxicol Pathol. 2015;43:959–83. https://doi.org/10.1177/0192623315591171.

Article  CAS  PubMed  Google Scholar 

Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs. 2008;22:315–29. https://doi.org/10.2165/00063030-200822050-00004.

Article  CAS  PubMed  Google Scholar 

Gonçalves J, Caliceti P. Optimizing pharmacological and immunological properties of therapeutic proteins through PEGylation: investigating key parameters and their impact. Drug Des Devel Ther. 2024;18:5041–62. https://doi.org/10.2147/DDDT.S481420.

Article  PubMed  PubMed Central  Google Scholar 

Ivens IA, Baumann A, McDonald TA, et al. PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers. Haemophilia. 2013;19:11–20. https://doi.org/10.1111/j.1365-2516.2012.02931.x.

Article  CAS  PubMed  Google Scholar 

Veronese FM, Pasut G. Pegylation, successful approach to drug delivery. Drug Discov Today. 2005;10:1451–8. https://doi.org/10.1016/S1359-6446(05)03575-0.

Article  CAS  PubMed  Google Scholar 

Kubetzko S, Sarkar CA, Pluckthun A. Protein PEGylation decreases observed target association rates via a dual blocking mechanism. Mol Pharmacol. 2005;68:1439–54. https://doi.org/10.1124/mol.105.014910.

Article  CAS  PubMed  Google Scholar 

Gefen T, Vaya J, Khatib S, et al. The impact of PEGylation on protein immunogenicity. Int Immunopharmacol. 2013;15:254–9. https://doi.org/10.1016/j.intimp.2012.12.012.

Article  CAS  PubMed  Google Scholar 

Carcao M. Changing paradigm of prophylaxis with longer acting factor concentrates. Haemophilia. 2014;20(Suppl 4):99–105. https://doi.org/10.1111/hae.12405.

Article  CAS  PubMed  Google Scholar 

Wynn TT, Gumuscu B. Potential role of a new PEGylated recombinant factor VIII for hemophilia A. J Blood Med. 2016;7:121–8. https://doi.org/10.2147/JBM.S82457.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mullins ES, Stasyshyn O, Alvarez-Roman MT, et al. Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A. Haemophilia. 2017;23:238–46. https://doi.org/10.1111/hae.13119.

Article  CAS  PubMed  Google Scholar 

Santagostino E, Mancuso ME. Glycopegylated recombinant factor IX for hemophilia B in context. Drug Des Devel Ther. 2018;12:2933–43. https://doi.org/10.2147/DDDT.S121743.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li X, Zheng H, Yu MC, et al. Is PEGylated G-CSF superior to G-CSF in patients with breast cancer receiving chemotherapy? A systematic review and meta-analysis. Support Care Cancer. 2020;28:5085–97. https://doi.org/10.1007/s00520-020-05603-w.

Article  PubMed  PubMed Central  Google Scholar 

Hauser G, Awad T, Brok J, et al. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis c. Cochrane Database Syst Rev. 2014;2014:CD005441. https://doi.org/10.1002/14651858.CD005441.pub3.

Article  PubMed  PubMed Central  Google Scholar 

McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis c. Gastroenterology. 2002;123:1061–9. https://doi.org/10.1053/gast.2002.35950.

Article  CAS  PubMed  Google Scholar 

Irizarry Rovira AR, Bennet BM, Bolon B, et al. Scientific and regulatory policy committee points to consider: histopathologic evaluation in safety assessment studies for PEGylated pharmaceutical products. Toxicol Pathol. 2018;46:616–35. https://doi.org/10.1177/0192623318791801.

Article  CAS  PubMed  Google Scholar 

Schoenbrunn A, Juelke K, Reipert BM, Horling F, Turecek PL. Polyethylene glycol 20 kDa-induced vacuolation does not impair phagocytic function of human monocyte-derived macrophages. Front Immunol. 2022;13:894411. https://doi.org/10.3389/fimmu.2022.894411.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kozma GT, Shimizu T, Ishida T, Szebeni J. Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. Adv Drug Deliv Rev. 2020;154–155:163–75. https://doi.org/10.1016/j.addr.2020.07.024.

Article  CAS  PubMed  Google Scholar 

Gupta S, Lau K, Harding CO, et al. Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials. EBioMedicine. 2018;37:366–73. https://doi.